Methodological Challenges in Biomedical HIV Prevention Trials (2008)

Chapter: 5 Design Considerations: Adherence

Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF.

Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF.
Previous Chapter: 4 Design Considerations: Pregnancy
Page 119 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 119
Page 120 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 120
Page 121 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 121
Page 122 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 122
Page 123 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 123
Page 124 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 124
Page 125 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 125
Page 126 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 126
Page 127 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 127
Page 128 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 128
Page 129 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 129
Page 130 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 130
Page 131 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 131
Page 132 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 132
Page 133 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 133
Page 134 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 134
Page 135 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 135
Page 136 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 136
Page 137 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 137
Page 138 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 138
Page 139 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 139
Page 140 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 140
Page 141 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 141
Page 142 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 142
Page 143 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 143
Page 144 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 144
Page 145 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 145
Page 146 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 146
Page 147 Cite Bookmark
Suggested Citation: "5 Design Considerations: Adherence." Institute of Medicine. 2008. Methodological Challenges in Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press. doi: 10.17226/12056.
Save
Cancel
Page 147
Next Chapter: 6 Design Considerations: Recruitment and Retention
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.